The expected number of hospitalisations and beds needed due to pandemic influenza on a regional level in the Netherlands

Virus Research

Volumn 103, Issue 1-2, 2004, Pages 17-23

  Van Genugten, Marianne L L ^a,b   Heijnen, Marie Louise A ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b MAPI GROUP   (Netherlands)

Author keywords

Influenza; Pandemic; Preparedness; Scenario analysis

Indexed keywords

OSELTAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR;

ANALYTIC METHOD; CONFERENCE PAPER; HEALTH CARE UTILIZATION; HOSPITAL BED UTILIZATION; HOSPITALIZATION; HUMAN; INFLUENZA; LENGTH OF STAY; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; NETHERLANDS; PERIODIC MEDICAL EXAMINATION; PRIORITY JOURNAL; RISK ASSESSMENT;

ADOLESCENT; ADULT; AGED; BEDS; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; HEALTH SERVICES NEEDS AND DEMAND; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA, HUMAN; MIDDLE AGED; NETHERLANDS;

EID: 2442501142     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2004.02.007     Document Type: Conference Paper

References (34)

1. Baltussen R.M.P.M., Reinders A., Sprenger M.J.W., Postma M.J., Jager J.C., Ament A.J.H.A., Leidl R.M. Estimating influenza related hospitalization in the Netherlands. Epidemiol. Infect. 121:1998;129-138
2. Bartelds, A.I.M., 2000. Continue Morbiditeits Registration Peilstations Nederland 1999. NIVEL, Utrecht, August 2000.
3. Belshe R.B. Influenza as a zoonosis: how likely is a pandemic? Commentary. Lancet. 351:1998;460-461
4. De Bruijn, I.A., Nauta, J., Palache, A.M., 2002. Virosomal influenza subunit vaccine (Invivac): a safe and effective influenza vaccine with high efficacy in subjects with low pre-vaccination antibody titres. In: Proceedings of the First European Influenza Conference, St.-Julians, Malta, 20-23 October 2002. Conference program and abstracts (Abstractnr. W9-5).
5. De Jong J.C., Claas E.C.J., Osterhaus A.D.M.E. Influenza A(H5N1) in Hong Kong: voorbode van een pandemic of alleen een wetenschappelijk interessant verschijnsel en een nuttige oefening in pandemiologie? Nederlands Tijdschrift voor Geneeskunde. 142(22):1998;1252-1256
6. Gubareva L.V., Kaiser L., Hayden F.G. Influenza virus neuraminidase inhibitors. Lancet. 355:2000;827-835
7. Hayden, F.G., Perspectives on antivirals for influenza. In: Proceedings of the First European Influenza Conference, St.-Julians, Malta, 20-23 October 2002. Conference program and abstracts (Abstractnr. S4-3).
8. Hayden F.G., Osterhaus A.D.M.E., Treanor J.J., Fleming D.M., Aoki F.Y., Nicholson K.G., Bohnen A.M., Hirst H.M., Keene O., Wightman K. Efficacy and safety of the neuraminidase inhibitor Zanamivir in the treatment of influenza virus infections. New Engl. J. Med. 337:1997;874-880
9. Hayden F.G., Atmar R.L., Schilling M., Johnson C., Poretz D., Paar D., Huson L., Ward P., Mills R.G. Oseltamivir Study Group Use of the selective oral neuraminidase inhibitor to prevent influenza. New Engl. J. Med. 341:1999;1336-1343
10. Hayden F.G., Gubareva L.V., Monto A.S., Klein T.C., Elliott M.J., Hammond J.M., Sharp S.J., Ossi M.J. Inhaled Zanamivir for the prevention of influenza in families. New Engl. J. Med. 343:2000;1282-1289
11. Hedrick J.A., Barzilai A., Behre U., Henderson F.W., Hammond J., Reilly L., Keene O. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediat. Infect. Dis. J. 19:2000;410-417
12. Knottnerus J.A., Metsemakers J., Höppener P., Limonard C. Chronic illness in the community and the concept of 'social prevalence'. J. Family Pract. 9:1992;15-21
13. Lalezari J., Campion K., Keene O., Silagy C. Zanamivir for the treatment of influenza A and B infection in high risk patients. Arch. Intern. Med. 161:2001;212-217
14. Lamberts H., Hofmans-Okkes I. Episode of care: a core concept in family practice. J. Family Pract. 42:1996;161-167
15. Mäkelä M.J., Pauksens K., Rostila T., Fleming D.M., Man C.Y., Keene O.N., Webster A. Clinical efficacy and safety of the orally inhaled neuaraminadase inhibitor Zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J. Infect. 40:2000;42-48
16. Meiss-de Haas, Ch.L., Schenk, H., Schouwerwou, R.J., Kliphuis, L., van der Velden, J., 2002. Regional pandemic planning in the Netherlands. In: Proceedings of the First European Influenza Conference, St.-Julians, Malta, 20-23 October 2002. Conference program and abstracts (Abstractnr. P-W3-2).
17. Meltzer M.I., Cox N.J., Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg. Infect. Dis. 5:1999;659-671
18. MIST Study Group, 1998. Randomised trial of efficacy and safety of inhaled Zanamivir in treatment of influenza A and B virus infections. Lancet 352 (1998) 1877-1881.
19. Monto A.S., Robinson D.P., Herlocher M.L., Hinson J.M., Elliott M.J., Crisp A. Zanamivir in the prevention of influenza among healthy adults. A randomized controlled trial. JAMA. 282:1999;31-35
20. Murphy K.R., Eivindson A., Pauksens K., Stein W.J., Tellier G., Watts R., Leophonte P., Sharp S.J., Loeschel E. Efficacy and safety of inhaled Zanamivir for the treatment of influenza in patients with asthma or COPD - a double-blind, randomised, placebo-controlled, multicentre study. Clin. Drug Invest. 20(5):2000;337-349
21. Nicholson K.G., Aoki F.Y., Osterhaus A.D.M.E., Trottier S., Carewicz O., Mercier C.H., Rode A., Kinnersley N., Ward P. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet. 355:2000;1845-1850
22. Palache A.M., Brands R., van Scharrenburg G.J.M. Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J. Infect. Dis. 176(Suppl. 1):1997;S20-S23
23. Potter, C.W., 1998. Chronicle of influenza pandemics. In: Nicholson, K.G., Webster, R.G., Hay, A.J. (Eds.), Textbook of Influenza. Blackwell Science, Oxford, Chapter 1, 1998.
24. RIVM, 2001. http://www.zorgatlas.nl.
25. Treanor J.J., Hayden F.G., Vrooman P.S., Barbarash R., Bettis R., Riff D., Singh S., Kinnersley N., Ward P. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. A randomized controlled trial. JAMA. 283:2000;1016-1024
26. Vademecum of Health Statistics in the Netherlands (Vademecum gezondheidsstatistiek Nederland), 1999. Centraal Bureau voor de Statistiek, Voorburg/Heerlen, 1999.
27. van Genugten, M.L.L., Rutten, F.F.H., Jager, J.C., 1996. Scenario development and costing in health care. Methodological Accomplishments and Practical Guidelines. International Books, 1996. ISBN 90 6224 877 2.
28. van Genugten, M.L.L., Heijnen, M.L.A., Jager, J.C., 2002. Scenario analysis of the expected number of hospitalisations and deaths due to pandemic influenza in the Netherlands. RIVM Report 282701002/2002, Bilthoven, The Netherlands. http://www.rivm.nl/bibliotheek/rapporten/282701002.pdf.
29. van Weel C. What our practices teach us? Brit. J. Gen. Pract. 42:1993;206-209
30. Voeten J.T.M., Brands R., Palache A.M., van Scharrenburg G.J.M., Rimmelzwaan G.F., Osterhaus A.D.M.E., Claas E.C.J. Characterization of high-growth reassortant influenza A viruses generated in MDCK cells cultured in serum-free medium. Vaccine. 17:1999;1942-1950
31. + cytotoxic T lymphocytes. Vaccine. 19:2000;522-530
32. Welliver R., Monto A.S., Carewicz O., Schatteman E., Hassman M., Hedrick J., Jackson H.C., Huson L., Ward P. Oxford JS for the Oseltamivir Post Exposure Prophylaxis Investigator Group. Effectiveness of oseltamivir in preventing influenza in household contacts. A randomized clinical trial. JAMA. 285:2001;748-754
33. Whitley R.J., Hayden F.G., Reisinger K.S., Young N., Dutkowski R., Ipe D., Mills R.G., Ward P. Oral oseltamivir treatment of influenza in children. Pediat. Infect. Dis. J. 20:2001;127-133
34. WHO, 1999. Department of Communicable Disease Surveillance and Response. Influenza pandemic plan. The role of the WHO and guidelines for national and regional planning, April 1999. http://www.who.int/emc-documents/influenza.